MediWound (NASDAQ:MDWD) Upgraded to “Sell” at StockNews.com

MediWound (NASDAQ:MDWD) was upgraded by stock analysts at StockNews.com to a “sell” rating in a report issued on Thursday.

Several other research firms have also recently commented on MDWD. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 price objective on shares of MediWound in a research report on Tuesday. Maxim Group increased their price objective on MediWound from $25.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday.

MediWound Trading Up 2.8 %

Shares of NASDAQ MDWD traded up $0.56 during mid-day trading on Thursday, reaching $20.89. 232,642 shares of the company’s stock were exchanged, compared to its average volume of 112,064. MediWound has a twelve month low of $7.10 and a twelve month high of $24.00. The firm has a market capitalization of $193.86 million, a price-to-earnings ratio of -15.14 and a beta of 0.81. The business has a fifty day simple moving average of $16.84 and a 200 day simple moving average of $15.38.

MediWound (NASDAQ:MDWD) last announced its earnings results on Wednesday, May 29th. The biopharmaceutical company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.01. MediWound had a negative net margin of 64.24% and a negative return on equity of 21.67%. The firm had revenue of $4.96 million for the quarter, compared to the consensus estimate of $4.65 million. Equities research analysts predict that MediWound will post -1.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

Several institutional investors and hedge funds have recently added to or reduced their stakes in MDWD. Janney Montgomery Scott LLC bought a new stake in MediWound during the first quarter worth about $427,000. Silverberg Bernstein Capital Management LLC bought a new stake in shares of MediWound during the 4th quarter worth approximately $803,000. Sargent Investment Group LLC boosted its holdings in shares of MediWound by 7.0% in the 4th quarter. Sargent Investment Group LLC now owns 109,194 shares of the biopharmaceutical company’s stock valued at $1,111,000 after buying an additional 7,125 shares during the last quarter. Yelin Lapidot Holdings Management Ltd. grew its stake in shares of MediWound by 45.7% in the fourth quarter. Yelin Lapidot Holdings Management Ltd. now owns 125,493 shares of the biopharmaceutical company’s stock valued at $1,276,000 after buying an additional 39,348 shares in the last quarter. Finally, Essex Investment Management Co. LLC increased its holdings in MediWound by 241.6% during the first quarter. Essex Investment Management Co. LLC now owns 132,487 shares of the biopharmaceutical company’s stock worth $1,888,000 after buying an additional 93,705 shares during the last quarter. 46.83% of the stock is owned by institutional investors.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.